Hospital doctors are required to provide patient data and indications for pharmaceutical use and dosage online, and the pharmaceutical validated by the system is released at the hospital pharmacy. If the patient is considered as a “non-responder” based on disease progression, progression-related death, or an excessively high toxicity level for continuing treatment, the manufacturers are expected to bear a certain proportion of the pharmaceutical costs. For example, during the initial six weeks of treatment with Avastin, half the cost is bom by the pharmaceutical company, and the other half by the NHS. After this period, all the cost is born by the NHS if the pharmaceutical is found effective, but for doses administered above a certain threshold, the pharmaceutical company has to reimburse the entire cost. The risk-sharing arrangements for the same pharmaceutical are sometimes different depending on the indication.